Oral SVMP inhibitors snakebite trial, Liverpool School sponsors
Summary
ClinicalTrials.gov registered a new interventional study sponsored by the Liverpool School of Tropical Medicine investigating oral SVMP (snake venom metalloproteinase) inhibitors as a treatment for snakebite. The Phase I/II clinical trial will enroll participants to evaluate the safety and efficacy of the oral inhibitor formulation. This registration applies to clinical investigators and healthcare providers involved in snakebite treatment research.
What changed
A new clinical trial (NCT07500233) was registered on ClinicalTrials.gov for an oral SVMP inhibitor candidate being developed for snakebite envenomation treatment. The Liverpool School of Tropical Medicine is sponsoring this Phase I/II study which will assess the safety, pharmacokinetics, and efficacy of the oral formulation in human participants.\n\nClinical investigators and healthcare institutions involved in venom research or tropical medicine should be aware of this trial registration. Sites may need to prepare for potential enrollment if affiliated with the sponsor. This is an informational registration entry with no immediate compliance deadlines for external parties.
Source document (simplified)
Show glossary
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.